FIELD: biotechnology.
SUBSTANCE: completely human antibodies that bind either to toxin A, or to toxin B Clostridium difficile, or both to toxin A and toxin B. Formulations containing these antibodies and methods for their application are also described. The antibodies of the present invention are useful for neutralisation of toxins from C. difficile, thus providing agents for treatment of disease and symptoms associated with C. difficile infection, including an agent for treatment of diarrhea or pseudomembranous colitis caused by C. difficile. Antibodies may also limit the severity and/or duration of the underlying disease or limit the amount, duration and/or severity of disease relapse or exacerbation due to the presence of C. difficile.
EFFECT: antibodies of this invention may also be suitable for infection diagnosis.
34 cl, 5 dwg, 10 tbl, 11 ex
| Title | Year | Author | Number |
|---|---|---|---|
| HUMAN ANTIBODIES TO Fel d1 AND METHODS OF USE THEREOF | 2013 |
|
RU2658491C2 |
| HUMAN RET-BINDING ANTIBODIES AND METHODS OF USE THEREOF | 2020 |
|
RU2821548C2 |
| HIGH-AFFINITY HUMAN ANGIOPOIETIN-2 ANTIBODIES | 2010 |
|
RU2545399C2 |
| ANTIBODIES FOR TREATMENT OF INFECTION AND DISEASES ASSOCIATED WITH CLOSTRIDIUM DIFFICILE | 2011 |
|
RU2630663C9 |
| HUMANIZED TAU-ANTIBODY | 2013 |
|
RU2644242C2 |
| HUMANISED ANTIBODY TO BETA AMYLOID | 2007 |
|
RU2498999C2 |
| HIGH-AFFINITY HUMAN IL-4 RECEPTOR ANTIBODIES | 2007 |
|
RU2445318C2 |
| COMPOSITIONS AND METHODS RELEVANT TO MUTANT TOXIN FROM CLOSTRIDIUM DIFFICILE | 2013 |
|
RU2630671C2 |
| COMPOSITIONS RELATED TO CLOSTRIDIUM DIFFICILE MUTANT TOXIN, AND METHODS OF APPLICATION THEREOF | 2012 |
|
RU2592686C2 |
| ANTIBODIES AGAINST HUMAN GDF8 | 2011 |
|
RU2567805C2 |
